Case Reports

Section edited by Alfred Zippelius, MD

Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.

Previous Page Page 2 of 2 Next Page
  1. Case report

    Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid

    To date, patients with pre-existing autoimmune conditions have been excluded from immunotherapy trials out of concern for severe autoimmune exacerbations.

    Kristen M. Beck, Joanna Dong, Larisa J. Geskin, Vincent P. Beltrani, Richard G. Phelps, Richard D. Carvajal, Gary Schwartz, Yvonne M. Saenger and Robyn D. Gartrell

    Journal for ImmunoTherapy of Cancer 2016 4:20

    Published on: 19 April 2016

  2. Case report

    Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

    Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been recently approved for treatment of patients with metastatic mela...

    Viktor H. Koelzer, Sacha I. Rothschild, Deborah Zihler, Andreas Wicki, Berenika Willi, Niels Willi, Michèle Voegeli, Gieri Cathomas, Alfred Zippelius and Kirsten D. Mertz

    Journal for ImmunoTherapy of Cancer 2016 4:13

    Published on: 15 March 2016

  3. Case report

    Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab

    Immune related adverse events affecting various organ systems are a recognized potential consequence of immune checkpoint inhibition. However, autoimmune inner ear disease is one complication not previously as...

    Matthew Zibelman, Natasha Pollak and Anthony J Olszanski

    Journal for ImmunoTherapy of Cancer 2016 4:8

    Published on: 16 February 2016

  4. Short report

    Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

    Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops brain metastases, which have been associated with poor survival and are often treated with radiation. Therefore...

    Jonathan D. Schoenfeld, Anand Mahadevan, Scott R. Floyd, Michael A. Dyer, Paul J. Catalano, Brian M. Alexander, David F. McDermott and Irving D. Kaplan

    Journal for ImmunoTherapy of Cancer 2015 3:50

    Published on: 15 December 2015

  5. Case report

    Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations

    Mismatch repair deficiency (MMRD) is a common pathway of malignant transformation accounting for approximately 15–20 % of human carcinogensis. It has been postulated that MMRD increases tumor antigenicity and ...

    Michael P. Castro and Neal Goldstein

    Journal for ImmunoTherapy of Cancer 2015 3:58

    Published on: 15 December 2015

  6. Case Reports

    Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

    We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination ther...

    Nu T. Lu, Jeffrey Raizer, Erwin P. Gabor, Natalie M. Liu, James Q. Vu, Dennis J. Slamon and John L. Barstis

    Journal for ImmunoTherapy of Cancer 2015 3:41

    Published on: 15 September 2015

  7. Research article

    Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

    Osteosarcoma is one of the most common bone cancers in children. Most patients with metastatic osteosarcoma die of pulmonary disease and limited curative therapeutic options exist for such patients. We have pr...

    Danielle M Lussier, John L Johnson, Pooja Hingorani and Joseph N Blattman

    Journal for ImmunoTherapy of Cancer 2015 3:21

    Published on: 19 May 2015

  8. Case Report

    Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

    Antibodies that stimulate the immune system by targeting inhibitory T cell receptors were successfully introduced into oncological practice and are capable to overcome tumor-induced immune evasion. In particul...

    Heinz Läubli, Cathrin Balmelli, Matthias Bossard, Otmar Pfister, Kathrin Glatz and Alfred Zippelius

    Journal for ImmunoTherapy of Cancer 2015 3:11

    Published on: 21 April 2015

  9. Case report

    Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

    Although animal studies have shown that the immunomodulator ipilimumab causes inflammation of the myocardium, clinically significant myocarditis has been observed only infrequently. We report a case of suspect...

    Benjamin P Geisler, Roy A Raad, Diana Esaian, Elad Sharon and David R Schwartz

    Journal for ImmunoTherapy of Cancer 2015 3:4

    Published on: 17 February 2015

  10. Case report

    Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma

    We report on a 36-year-old woman treated with the anti PD-1 antibody Pembrolizumab for metastatic cutaneous melanoma in the first line setting. She achieved a complete response and then relapsed with metastase...

    Joshua S Manusow, Leila Khoja, Nataly Pesin, Anthony M Joshua and Efrem D Mandelcorn

    Journal for ImmunoTherapy of Cancer 2014 2:41

    Published on: 16 December 2014

  11. Case report

    Ipilimumab in patients with melanoma and autoimmune disease

    Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To d...

    Chrisann Kyi, Richard D Carvajal, Jedd D Wolchok and Michael A Postow

    Journal for ImmunoTherapy of Cancer 2014 2:35

    Published on: 14 October 2014

  12. Case report

    Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

    Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melano...

    Sowmya Ravi, Kristen Spencer, Mary Ruisi, Nageatte Ibrahim, Jason J Luke, John A Thompson, Keisuke Shirai, David Lawson, Heddy Bartell, Ragini Kudchadkar, Ngoc Thi Gunter, Janice M Mehnert and Evan J Lipson

    Journal for ImmunoTherapy of Cancer 2014 2:33

    Published on: 14 October 2014

  13. Case report

    Opportunistic infections in patients treated with immunotherapy for cancer

    Immunomodulatory antibodies that enhance the immune system to fight cancer are revolutionizing the treatment of patients with an expanding variety of malignancies. There is a unique spectrum of side effects as...

    Chrisann Kyi, Matthew D Hellmann, Jedd D Wolchok, Paul B Chapman and Michael A Postow

    Journal for ImmunoTherapy of Cancer 2014 2:19

    Published on: 18 June 2014

Previous Page Page 2 of 2 Next Page

Can't find what you are looking for?

Articles for this section are still being added to this new-look site. In the meantime you can still view this section on our old site.

JITC logo

Advertisement